'...and C is for Clioquinol' - the AbetaCs of Alzheimer's disease.
Alzheimer's disease (AD) is a devastating age-related neurodegenerative disorder that has been intensively studied over the last several years. In vitro and in vivo studies have led to an understanding of some of the physico-chemical properties of amyloid, a well-characterized hallmark of AD. Clioquinol is a drug that acts on amyloid by perturbing amyloid's metallo-chemistry, and Clioquinol treatment has been shown to be beneficial in a mouse model of AD. This short review examines the recent studies relating to Clioquinol and AD, and anticipates the imminent results of a Phase II trial of Clioquinol in AD, due in March 2002.
Melov
Simon
S
Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA. smelov@buckinstitute.org
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007464:Clioquinol / Q000494:pharmacology*; D004195:Disease Models, Animal; D051379:Mice; D008822:Mice, Transgenic; D018384:Oxidative Stress / Q000187:drug effects* / Q000502:physiology; D058225:Plaque, Amyloid / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D016229:Amyloid beta-Peptides; D002614:Chelating Agents; D007464:Clioquinol